Top Biotech Companies in Singapore (93)
Qritive makes cancer diagnosis fast, cheap, and accurate. Qritive develops AI-powered solutions that enable histopathologic diagnosisof cancer at scale. Our clinical-decision support system for pathologists unlocks efficiency and quality gain in diagnosis, which results in better patient outcome. It includes AI Modules, an Image Management System platform (Pantheon), and a network of pathologists on-demand for services (annotations, 2nd opinion...) Our digital...
ReSync coordinates labs, data, and AI models on one platform. Stop wrangling with emails and spreadsheets – find data and make decisions twice as fast.
AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance
In a rapidly changing industry, caregivers remain the constant. Every day they demonstrate their passion for helping people despite unprecedented pressure to increase access and quality of care with the same or fewer resources. Hillrom is driven by patient-centered care. Everything we do, and all our products and technologies, are designed to enhance outcomes for patients and caregivers. It starts...
Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies.
Standard BioTools's Top Stability & Growth Strengths
Investor Backing & Capital Strength: The sale of the SomaLogic business to Illumina provided substantial cash proceeds, leaving the company with a strong cash and investment position to pursue M&A. Management cites enhanced balance sheet flexibility to support an inorganic growth strategy.
Cost & Operational Efficiency: Management has fully operationalized significant annualized cost savings and reduced operating expenses. Targets for positive adjusted EBITDA and adjusted cash flow by the end of 2026 indicate continued focus on efficiency.
Strong Market Position & Advantage: The company is widely recognized as a leader in mass cytometry and imaging mass cytometry through its CyTOF and Hyperion platforms. Ongoing platform updates and ecosystem signals point to durable leadership within these niches.
Carcell Biopharma ("Carcell") is a global biotech company launched by EVX Ventures. With an innovative “hub-and-spoke” business model, Carcell accelerates innovations in and translation of next-generation cell and gene therapies. Carcell has two lead technology platforms. The first technological platform creates engineered red blood cells (eRBC) for allogeneic cell therapy against autoimmune diseases and cancer. The second technological platform is...
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
Syngenta Group is a leading global agricultural technology (AgTech) company headquartered in Basel, Switzerland. With over 50,000 employees across more than 90 countries, it provides farmers with innovative technology and expertise to increase productivity and ensure the growth of healthy, affordable, and sustainable food. The company is a world market leader in sustainable agriculture, offering a diverse portfolio of seeds...
Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and...
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to...
QIAGEN's Top Stability & Growth Strengths
Strong Market Position & Advantage: Leadership in latent TB blood testing (QuantiFERON) and entrenched sample‑preparation technologies is reinforced by global guidelines and deep workflow stickiness. The company is also building share in digital PCR and competes credibly in syndromic panels despite strong incumbents.
Resilient & Sustainable Growth: Net sales grew in 2025 with guidance for further mid‑single‑digit growth in 2026, and earnings are guided to improve. Growth is increasingly driven by non‑COVID ‘pillars’ with recurring consumables and software that generally support steadier demand.
Future-Ready Strategy: Management pruned non‑core lines (e.g., NeuMoDx exit) and refocused investment on five growth pillars with multi‑year targets through 2028. Ongoing menu expansions, regulatory submissions, and targeted M&A (e.g., single‑cell and clinical genomics software) indicate continued positioning for scaled, profitable growth.
Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency...
We are a bunch of highly experienced doctors, technologists, insurance experts and managed care practitioners who believe that we can use technology to improve the quality of Asian healthcare while lowering costs. We also know what works in Asia, and we brought best-in-class technologies from around the world on to one platform to make that belief a reality. We get...
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Illumina's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Illumina maintains dominant leadership in short-read NGS with a broad installed base, end-to-end workflows, and wide adoption across research and clinical markets. This entrenched position supports recurring consumables pull-through and reinforces competitive advantage.
Profitability: Feedback suggests profitability and margins improved with a stronger year-end quarter, rising EPS, and robust free cash generation supporting restructuring and reinvestment. Operating performance strengthened year over year, indicating better cost discipline and a healthier earnings profile.
Innovation-Driven Growth: Feedback suggests product and technology innovation—including NovaSeq X adoption and advances in AI/informatics—is driving utilization and clinical momentum. Partnerships and acquisitions broaden multiomics capabilities and underpin a roadmap focused on further cost and throughput gains.
The Lee Kong Chian School of Medicine (LKCMedicine) trains doctors with a focus on patient-centered care, integrating precision medicine, Artificial Intelligence (AI) in healthcare, and medical humanities into its undergraduate medical degree program.
Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include...
Nutrition Technologies (“NT”) researches, manufactures and supplies sustainable agricultural inputs (animal feed ingredients, biofertilisers and biological agents). NT uses its unique proprietary biotechnology and Black Soldier Fly Larvae (BSFL) rearing process to recycle nutrients from agricultural and food processing by-products. Their insect-based products help feed the growing agriculture and feed industries around the world. These products are suitable for application...
Cordlife India is a fully owned subsidiary of Cordlife Group Limited. The Indian Laboratory is AABB accredited and operates the most advanced umbilical cord and cord blood processing, testing and cryopreservation facility in the country, with a storage capacity of 200,000 cord blood units scalable by another few lakh units. The state-of-the-art laboratory is equipped with the latest and the most...
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery...
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and...
Catalent, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyses consistently place Catalent among the top global CDMOs, with meaningful presence in outsourced finished‑dose approvals and a broad end‑to‑end network. Its scale across oral, sterile, biologics, and cell & gene therapy supports late‑stage and commercial programs globally.
Investor Backing & Capital Strength: Novo Holdings’ completed acquisition provides deep‑capital sponsorship and strategic validation, with U.S./EU clearance reinforcing the platform’s importance. Related transactions around sterile sites highlight the strategic value of capabilities aligned to high‑demand medicines.
Future-Ready Strategy: Private ownership and a refreshed operating model aim to focus investment on biologics, cell & gene therapy, and clinical supply. GLP‑1–linked demand signals and capacity plans into the coming years indicate preparedness for sustained growth.
